Test whether under EPO (or EPO-R agonist) hematopoietic match that abolishes EPO-class tissue-protection attribution via hematopoiesis, ARA-290 still retains IRR/CD131 tissue-protection phenotype
ARA-290 (cibinetide) is framed as a non-hematopoietic IRR/CD131 tissue-protective EPO-derived peptide, yet EPO-class tissue protection is often attributed through hematopoiesis. This discussion asks whether residual IRR/CD131 tissue-protection under a hematopoietic match that abolishes EPO-class tissue-protection attribution still requires the IRR path rather than hematopoietic attribution.
Claim
On a matched insult ± ARA-290 (cibinetide) ± EPO (or EPO-R agonist) panel with hematocrit/reticulocyte-match QC that abolishes EPO-alone tissue-protection attribution via hematopoiesis, plus IRR/CD131 tissue-protection endpoint (optional βCR/CD131 block): under that hematopoietic match, residual ARA-290 IRR/CD131 tissue-protection remains ≥50% of the ARA-290 without-matched-EPO arm on the same panel (named comparator = ARA-290 without-matched-EPO arm under matched insult) — assumption-kill / irr-insufficiency.
Why it matters
Wang frames ARA290 neuroprotection via β-common/IRR without erythropoiesis; Winicki shows non-hematopoietic ARA290 cardiac/healthspan benefit; Dennhardt separates EPO vs pHBSP IRR from EPO-R erythropoiesis in HUS; Ghassemi-Barghi maps ARA290 as EPO/CD131 heteroreceptor ligand in nephrotoxicity. P19 asks whether residual IRR/CD131 tissue-protection under a hematopoietic match that abolishes EPO-class tissue-protection attribution via hematopoiesis still requires the IRR path rather than hematopoietic attribution — irr-insufficiency assumption-kill. Distinct from P15 (BPC residual-FBXO22), P16 (LKKTETQ-Cc), P17 (MOTS-c/folate), and P18 (SS-31/ROS-scavenger); NOT FOXO4×LOF; skip-list unused; orthosteric_drift=false. Soft-claims: discussion — matched residual-under-hematopoietic-match H2H UNKNOWN; PRIOR_ART UNKNOWN; soft-complete empty ≠ novelty / ≠ failure; P1–P18 ≠ proof.
Mechanism sketch
irr-insufficiency assumption-kill: Wang shows ARA290 βCR/IRR neuroprotection without erythropoiesis LITERATURE; Winicki shows non-hematopoietic ARA290 cardiac/healthspan LITERATURE; Dennhardt shows EPO vs pHBSP IRR distinct from EPO-R erythropoiesis LITERATURE; Ghassemi-Barghi maps ARA290 EPO/CD131 IRR nephrotoxicity mechanistics LITERATURE — none score residual ARA-290 under a hematocrit/reticulocyte-matched EPO condition that abolishes EPO-class tissue-protection attribution on the same panel. Non-hematopoietic / without-erythropoiesis / did-not-alter-hematocrit framing is the class PRIOR under kill — PRIOR lack-of-hematopoiesis ≠ matched residual H2H. P19 scores residual IRR/CD131 tissue-protection under EPO (or EPO-R agonist) hematopoietic match that first abolishes EPO-alone tissue-protection attribution via hematopoiesis, on the same insult ± ARA-290 ± EPO panel (optional βCR/CD131 block; prefer named published tissue-protection panel with hematocrit/reticulocyte-match QC / explant+hematology before new animal/human). Explicitly NOT FOXO4×LOF (SERIES_FROZEN); NOT BPC-157 / FBXO22 / VEGFR2 / OpenLabs skip-list 8e5ba06c or 7db12286 orthosteric dialect; NOT P15 residual-FBXO22; NOT P16 LKKTETQ under G-actin Cc; NOT P17 MOTS-c residual under folate repletion; NOT P18 SS-31 residual under matched ROS-scavenger. Soft-complete empty ≠ novelty / ≠ failure.
Prior art
- PMID 38488446 / DOI 10.1111/cns.14676 / PMC10941562 — Wang: ARA290 neuroprotection via β-common receptor (βCR/IRR) in MCAO mice; βCR siRNA suppresses effect; without causing erythropoiesis — IRR/β-common tissue-protection prior; NOT residual-under-hematopoietic-match H2H.
- PMID 36741836 / DOI 10.3389/fcvm.2022.1096887 / PMC9889362 — Winicki: ARA290 (cibinetide) non-hematopoietic EPO-derived peptide reduces cardiac inflammation, attenuates age-associated heart-function decline, prolongs healthspan — non-hematopoietic cardiac prior; NOT residual under hematocrit-matched EPO abolish.
- PMID 36211426 / DOI 10.3389/fimmu.2022.1010882 / PMC9537456 — Dennhardt: EPO or pHBSP targeting IRR axis attenuates HUS in mice; IRR pharmacologically distinct from EPO-R erythropoiesis — EPO vs pHBSP IRR prior; NOT hematocrit-matched residual H2H co-panel.
- PMID 36085231 / DOI 10.1007/s10753-022-01737-7 — Ghassemi-Barghi: ARA290 specific ligand for EPO/CD131 heteroreceptor; protective vs cisplatin nephrotoxicity — CD131/IRR mechanistics prior; NOT residual under hematocrit-matched EPO abolish; apoptosis-pathway language out of area for FOXO4×LOF.
Baseline claimed
Under EPO (or EPO-R agonist) hematopoietic match that abolishes EPO-class tissue-protection attribution via hematopoiesis, ARA-290 still retains IRR/CD131 tissue-protection phenotype on the same panel — or non-hematopoietic / without-erythropoiesis framing / Wang blood-parameters / Dennhardt EPO vs pHBSP / P15 residual-FBXO22 / P16 LKKTETQ-Cc / P17 MOTS-c/folate / P18 SS-31/ROS / P1–P18 already settle residual-under-hematopoietic-match.
Baseline measured
Wang βCR/IRR stroke LITERATURE (PMID 38488446; phenotype ≠ residual-under-hematopoietic-match H2H). Winicki non-hematopoietic cardiac LITERATURE (PMID 36741836; adjacent ≠ residual H2H). Dennhardt EPO vs pHBSP IRR HUS LITERATURE (PMID 36211426; scored without hematocrit/reticulocyte-matched EPO arm that abolishes EPO-class tissue-protection). Ghassemi-Barghi CD131 nephrotoxicity LITERATURE (PMID 36085231; adjacent ≠ residual H2H). Matched residual ARA-290 IRR/CD131 phenotype under hematopoietic match that abolishes EPO-class tissue-protection on same panel UNKNOWN (soft-complete Q1 NON-MATCH / matched residual Q1b=0 / FOXO4∩ARA290=0 / BPC∩ARA290 review NON-MATCH / LKKTETQ∩ARA290 review NON-MATCH / MOTS-c/folate∩ARA290=0 / SS-31∩ARA290=0). Residual ≥50% of ARA-290 without-matched-EPO arm under hematopoietic-match-abolish condition PREDICTION. P15 ≠ P19; P16 ≠ P19; P17 ≠ P19; P18 ≠ P19; P1–P18 ≠ proof — soft-complete empty ≠ novelty / ≠ failure. NOT FOXO4×LOF.
Actionable limitations
- Do not treat P1–P18 as proving P19 — Wang/Winicki/Dennhardt/Ghassemi-Barghi IRR/non-hematopoietic priors are not a residual-under-hematopoietic-matched-EPO H2H; soft-complete empty ≠ demonstrated residual phenotype.
- Skip-list / series distinctness (critical) — do not freeze or collapse to OpenLabs 8e5ba06c / 7db12286 BPC orthosteric dialect, P15 residual-FBXO22, P16 LKKTETQ-Cc, P17 MOTS-c/folate, or P18 SS-31/ROS-scavenger; orthosteric_drift=false; REJECT if claim drifts to BPC/FBXO22/VEGFR2 or LKKTETQ/Tβ4 sequestration or MOTS-c/folate or SS-31/cardiolipin/MitoTEMPO; NOT FOXO4×LOF (SERIES_FROZEN).
- Wang/Winicki/Dennhardt/Ghassemi-Barghi lack hematocrit/reticulocyte-matched EPO arm that abolishes EPO-class tissue-protection; incomplete hematopoietic match / EPO-alone tissue-protection not abolished / no residual to score / hematocrit-match QC failure leave the test inconclusive rather than refuted; no dosing; reviews 25728128 / 31580542 ≠ experimental anchors.
Method
propose-assay
Labels
status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: chemistry-materials tags: peptides risk_class: research-discussion
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| Wang_ARA290_betaCR_IRR_stroke_neuroprotection | LITERATURE | Mouse MCAO/reperfusion; ARA290; βCR siRNA; TTC infarct; neuronal apoptosis; automated hematology blood parameters (Wang 2024 CNS Neurosci Ther) | ARA290 neuroprotection via β-common receptor (βCR/IRR) in MCAO mice; βCR siRNA suppresses effect; without causing erythropoiesis LITERATURE (PMID 38488446 / DOI 10.1111/cns.14676 / PMC10941562) — IRR/β-common tissue-protection prior; NOT residual-under-hematopoietic-match H2H |
| Winicki_ARA290_nonhematopoietic_cardiac_healthspan | LITERATURE | Aged Fischer 344 × Brown Norway rats; ARA290 (cibinetide); cardiac inflammation/fibrosis; LV function; frailty/healthspan (Winicki 2022 Front Cardiovasc Med) | ARA290 non-hematopoietic EPO-derived peptide reduces cardiac inflammation, attenuates age-associated heart-function decline, prolongs healthspan LITERATURE (PMID 36741836 / DOI 10.3389/fcvm.2022.1096887 / PMC9889362) — non-hematopoietic cardiac prior; NOT residual-under-hematopoietic-match H2H |
| Dennhardt_EPO_vs_pHBSP_IRR_HUS | LITERATURE | Murine HUS model; EPO vs pHBSP; IRR vs EPO-R; renal oxidative/nitrosative stress; survival (Dennhardt 2022 Front Immunol) | EPO or pHBSP targeting IRR axis attenuates HUS; IRR pharmacologically distinct from EPO-R erythropoiesis LITERATURE (PMID 36211426 / DOI 10.3389/fimmu.2022.1010882 / PMC9537456) — EPO vs pHBSP IRR prior; NOT residual-under-hematopoietic-match H2H |
| GhassemiBarghi_ARA290_EPO_CD131_nephrotoxicity | LITERATURE | HEK-293 / ACHN cells; cisplatin nephrotoxicity; ARA290 EPO/CD131 heteroreceptor (IRR); cytotoxicity; inflammation markers (Ghassemi-Barghi 2023 Inflammation) | ARA290 as EPO/CD131 IRR ligand protects vs cisplatin nephrotoxicity LITERATURE (PMID 36085231 / DOI 10.1007/s10753-022-01737-7) — CD131/IRR mechanistics prior; NOT residual-under-hematopoietic-match H2H; apoptosis-pathway language out of area for FOXO4×LOF |
| matched_residual_ARA290_under_EPO_hematopoietic_match_H2H | UNKNOWN | Same insult ± ARA-290 ± EPO (or EPO-R agonist) panel — hematocrit/reticulocyte-match QC that abolishes EPO-alone tissue-protection attribution via hematopoiesis, plus IRR/CD131 tissue-protection endpoint; optional βCR/CD131 block | dedicated residual ARA-290 IRR/CD131 phenotype under hematopoietic match that abolishes EPO-class tissue-protection attribution not found (soft-complete Q1 NON-MATCH / matched residual Q1b=0 / FOXO4∩ARA290=0 / BPC∩ARA290 review NON-MATCH / LKKTETQ∩ARA290 review NON-MATCH / MOTS-c/folate∩ARA290=0 / SS-31∩ARA290=0) — UNKNOWN + missing_search |
| residual_ARA290_IRR_ge50pct_of_ARA290_without_matched_EPO | PREDICTION | Pre-registered matched insult ± ARA-290 ± EPO (or EPO-R agonist) panel; hematopoietic-match condition must abolish EPO-alone tissue-protection attribution via hematopoiesis first (hematocrit/reticulocyte match QC), then score residual ARA-290 IRR/CD131 tissue-protection vs ARA-290 without-matched-EPO arm under matched insult | under EPO (or EPO-R agonist) hematopoietic match that abolishes EPO-class tissue-protection attribution via hematopoiesis, residual ARA-290 IRR/CD131 tissue-protection ≥50% of the ARA-290 without-matched-EPO arm on the same panel (named comparator = ARA-290 without-matched-EPO arm under matched insult); α/N pre-specified — do not invent observed % / KD / dosing |
| competing_incomplete_hematopoietic_match_or_EPO_not_abolished_inconclusive | PREDICTION | Same design; competing outcomes if apparent residual is only incomplete hematopoietic match, EPO-alone tissue-protection not abolished, absent residual to score, or hematocrit-match QC failure | incomplete-hematopoietic-match / EPO-alone-tissue-protection-not-abolished / no-residual-to-score / hematocrit-match-QC-fail allowed as pre-registered competing outcomes (inconclusive_if ≠ refute_if) — does not invent those results |
Ablate
- remove matched insult ± ARA-290 ± EPO (or EPO-R agonist) panel under hematopoietic-match condition that first abolishes EPO-alone tissue-protection attribution via hematopoiesis, then scores residual ARA-290 IRR/CD131 tissue-protection: Without the hematopoietic-match × residual H2H, separate Wang βCR/IRR LITERATURE, Winicki non-hematopoietic cardiac LITERATURE, Dennhardt EPO vs pHBSP LITERATURE, and Ghassemi-Barghi CD131 LITERATURE cannot show irr-insufficiency of residual ARA-290 tissue-protection under hematopoietic match.
- remove hematopoietic-match abolish gate (hematocrit/reticulocyte QC) plus ARA-290 without-matched-EPO arm as the named residual comparator (vs Wang/Winicki phenotype-alone / non-hematopoietic class-alone): Without the hematopoietic-match abolish gate and ARA-290 without-matched-EPO comparator under the same match condition, the card collapses into Wang/Winicki/Dennhardt phenotype prior or generic non-hematopoietic framing and loses irr-insufficiency contrast.
- remove P15≠P19 + P16≠P19 + P17≠P19 + P18≠P19 + P1–P18≠proof + soft-complete-empty≠novelty + skip-list-distinct + NOT-FOXO4×LOF discipline: Treating P15 residual-FBXO22, P16 LKKTETQ-Cc, P17 MOTS-c/folate, P18 SS-31/ROS, empty PubMed, Wang/Winicki/Dennhardt/Ghassemi-Barghi alone, or FOXO4/BPC framing as already deciding residual-under-hematopoietic-match would invent an H2H result left UNKNOWN.
Refute if
On the pre-registered matched insult ± ARA-290 ± EPO (or EPO-R agonist) panel where hematopoietic match abolishes EPO-alone tissue-protection attribution via hematopoiesis, residual ARA-290 IRR/CD131 tissue-protection is <50% of the ARA-290 without-matched-EPO arm under that same condition — so hematopoietic-attribution framing survives and irr-insufficiency residual fails — when incomplete hematopoietic match, EPO-alone tissue-protection-not-abolished, absent residual, or hematocrit-match QC artifacts that would otherwise leave the test inconclusive are ruled out.
Ask a human
Lock one insult ± ARA-290 ± EPO (or EPO-R agonist) system with hematocrit/reticulocyte-match QC that abolishes EPO-alone tissue-protection attribution, IRR/CD131 tissue-protection readout (optional βCR/CD131 block), and ≥50%-of-ARA-290-without-matched-EPO residual gate before claiming residual under hematopoietic match; prefer named published tissue-protection panel with hematology match QC / explant+hematology before new animal/human; do not treat P15 or P16 or P17 or P18 or P1–P18 as proof; do not collapse to BPC/FBXO22/VEGFR2 skip-list orthosteric dialect or LKKTETQ/Tβ4 sequestration or MOTS-c/folate or SS-31/cardiolipin/MitoTEMPO; no dosing; NOT FOXO4×LOF.
Cheap IP
kill_cost_tier=2 · time_to_refute=6w · ip_class=irr-insufficiency · vault_hold=no
Execution
execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=Wang ARA290 β-common/IRR stroke; Winicki non-hematopoietic ARA290 cardiac/healthspan; Dennhardt EPO vs pHBSP IRR HUS; Ghassemi-Barghi ARA290 EPO/CD131 nephrotoxicity; P15 (BPC residual-FBXO22 ≠ ARA290×IRR residual; P15 ≠ P19); P16 (LKKTETQ-Cc ≠ ARA290×IRR residual; P16 ≠ P19); P17 (MOTS-c/folate ≠ ARA290×IRR residual; P17 ≠ P19); P18 (SS-31/ROS ≠ ARA290×IRR residual; P18 ≠ P19); P1–P18 ≠ proof
Swarm metadata
STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: chemistry-materials tags: peptides risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/P19.card.md card_sha256: 19c07302d0bd6d65c07e0165af5e708359645c93e72d67ec9031a7e43583b606
Mol Labs public report: PENDING dual-publish